A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution?

@inproceedings{Yang2014ACP,
  title={A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution?},
  author={Eugene Yang},
  booktitle={Vascular health and risk management},
  year={2014}
}
Over the past few years, three novel oral anticoagulants, dabigatran, rivaroxaban, and apixaban, have been approved in the USA and Europe to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, and the results of a Phase III trial for a fourth novel oral anticoagulant, edoxaban, have recently been published. The aim of this review is to examine this indication from a clinician's perspective, highlighting efficacy and safety results from the major… CONTINUE READING
7 Citations
79 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 79 references

Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study

  • TB Larsen, LH Rasmussen, F Skjoth
  • J Am Coll Cardiol
  • 2013
Highly Influential
9 Excerpts

Eliquis (apixaban tablets, prescribing information). Available from: http://packageinserts.bms.com/pi/ pi_eliquis.pdf

  • Bristol-Myers Squibb
  • Accessed March 20,
  • 2014
Highly Influential
5 Excerpts

Eliquis (apixaban tablets) Summary of product characteristics

  • Bristol-Myers Squibb, Pfizer EEIG
  • Available from: http://www.ema. europa.eu/docs…
  • 2014
Highly Influential
2 Excerpts

Similar Papers

Loading similar papers…